Building Decision-Grade RWD Through Multi-Stakeholder Data Partnerships

• Share early learnings from developing a syndicated registry model, including how greater collaboration and transparency could strengthen confidence in RWE and support its acceptance for regulatory and HTA decision-making
• Examine how sharing data infrastructure, costs and research efforts across pharmaceutical companies and healthcare organisations can reduce the time, complexity and cost of generating high-quality RWE
• Discuss the practical challenges of establishing these collaborative models, including aligning multiple stakeholders, determining fair market value for data and creating sustainable partnership frameworks

Speakers:

Melpomeni Styliadou

Vice President, Global Program Leader, Health Data Partnerships

Takeda Pharmaceutical